Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BCAT NYSE:CET NYSE:GSBD NYSE:HQL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCATBlackRock Capital Allocation Term Trust$15.03+0.6%$14.98$12.91▼$16.80$1.61B0.76532,211 shs679,402 shsCETCentral Securities$49.99+0.0%$48.63$40.24▼$50.55$1.45B0.8424,979 shs21,480 shsGSBDGoldman Sachs BDC$11.45+0.2%$11.48$9.51▼$14.54$1.30B0.75595,284 shs448,192 shsHQLabrdn Life Sciences Investors$13.92+0.1%$13.30$10.55▼$15.68$401.61M0.7599,241 shs100,436 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCATBlackRock Capital Allocation Term Trust+0.60%+1.49%+0.57%+0.97%-7.37%CETCentral Securities+0.04%+0.06%+3.14%+7.57%+13.08%GSBDGoldman Sachs BDC+0.26%+0.09%+0.75%+0.88%-18.37%HQLabrdn Life Sciences Investors+0.36%+0.94%+5.22%+13.45%-8.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCATBlackRock Capital Allocation Term TrustN/AN/AN/AN/AN/AN/AN/AN/ACETCentral SecuritiesN/AN/AN/AN/AN/AN/AN/AN/AGSBDGoldman Sachs BDC1.3347 of 5 stars0.53.02.50.03.40.01.9HQLabrdn Life Sciences InvestorsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCATBlackRock Capital Allocation Term Trust 0.00N/AN/AN/ACETCentral Securities 0.00N/AN/AN/AGSBDGoldman Sachs BDC 1.00Sell$10.00-12.63% DownsideHQLabrdn Life Sciences Investors 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest HQL, BCAT, CET, and GSBD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025GSBDGoldman Sachs BDCZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold ➝ Strong Sell(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCATBlackRock Capital Allocation Term Trust$197.67M8.17N/AN/AN/A∞CETCentral Securities$222.17M6.51N/AN/AN/A∞GSBDGoldman Sachs BDC$434.37M3.01$2.19 per share5.23$13.26 per share0.86HQLabrdn Life Sciences InvestorsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCATBlackRock Capital Allocation Term TrustN/AN/A0.00∞N/AN/AN/AN/AN/ACETCentral SecuritiesN/AN/A0.00∞N/AN/AN/AN/AN/AGSBDGoldman Sachs BDC$62.87M$1.269.086.25N/A36.17%13.95%6.17%11/6/2025 (Estimated)HQLabrdn Life Sciences InvestorsN/AN/A0.00∞N/AN/AN/AN/AN/ALatest HQL, BCAT, CET, and GSBD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025GSBDGoldman Sachs BDC$0.3950$0.38-$0.0150$0.34$94.55 million$90.97 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCATBlackRock Capital Allocation Term Trust$3.4022.63%N/AN/AN/ACETCentral Securities$2.304.60%N/AN/AN/AGSBDGoldman Sachs BDC$1.2811.18%N/A101.59%N/AHQLabrdn Life Sciences Investors$1.4010.06%N/AN/AN/ALatest HQL, BCAT, CET, and GSBD DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/6/2025GSBDGoldman Sachs BDCquarterly$0.3211.3%9/30/20259/30/202510/28/20258/11/2025HQLabrdn Life Sciences Investorsquarterly$0.4213.6%8/22/20258/22/20259/30/20258/8/2025GSBDGoldman Sachs BDCquarterly$0.031.05%8/29/20258/29/20259/15/20258/1/2025BCATBlackRock Capital Allocation Term Trustmonthly$0.272422.8%8/15/20258/15/20258/29/20257/1/2025BCATBlackRock Capital Allocation Term Trustmonthly$0.275522.5%7/15/20257/15/20257/31/20256/4/2025BCATBlackRock Capital Allocation Term Trustmonthly$0.278222.7%6/13/20256/13/20256/30/20256/4/2025CETCentral Securitiesquarterly$0.252.14%6/17/20256/17/20256/27/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCATBlackRock Capital Allocation Term TrustN/AN/AN/ACETCentral SecuritiesN/AN/AN/AGSBDGoldman Sachs BDC1.191.501.50HQLabrdn Life Sciences InvestorsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCATBlackRock Capital Allocation Term Trust36.12%CETCentral Securities8.68%GSBDGoldman Sachs BDC28.72%HQLabrdn Life Sciences Investors32.21%Insider OwnershipCompanyInsider OwnershipBCATBlackRock Capital Allocation Term TrustN/ACETCentral Securities9.50%GSBDGoldman Sachs BDC0.12%HQLabrdn Life Sciences Investors10.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCATBlackRock Capital Allocation Term Trust147,000107.46 millionN/ANot OptionableCETCentral Securities628.94 million26.19 millionNot OptionableGSBDGoldman Sachs BDCN/A114.11 million113.98 millionOptionableHQLabrdn Life Sciences InvestorsN/A28.87 million25.97 millionNot OptionableHQL, BCAT, CET, and GSBD HeadlinesRecent News About These CompaniesSamalin Investment Counsel LLC Buys Shares of 20,416 abrdn Life Sciences Investors $HQLAugust 29 at 6:33 AM | marketbeat.comabrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Sells 10,710 SharesAugust 27 at 11:16 AM | marketbeat.comSaba Capital Management, L.P. Sells 10,710 Shares of abrdn Life Sciences Investors (NYSE:HQL) StockAugust 26, 2025 | insidertrades.comHQL: We Should Be Accumulating During The WeaknessAugust 21, 2025 | seekingalpha.comabrdn Life Sciences Investors (NYSE:HQL) Sees Significant Drop in Short InterestAugust 19, 2025 | marketbeat.comabrdn Life Sciences Investors (NYSE:HQL) Holdings Lifted by LPL Financial LLCAugust 16, 2025 | marketbeat.comabrdn Life Sciences Investors (NYSE:HQL) Declares Quarterly Dividend of $0.42August 14, 2025 | marketbeat.comabrdn Life Sciences Investors declares $0.42 dividendAugust 12, 2025 | seekingalpha.comShaker Financial Services LLC Takes $297,000 Position in abrdn Life Sciences Investors (NYSE:HQL)August 6, 2025 | marketbeat.comAbrdn Life Sciences Investors (HQL) - Yahoo FinanceJuly 15, 2025 | finance.yahoo.comNYSE:HQL Financials | Abrdn Life Sciences Investors - Investing.comJuly 4, 2025 | investing.comHQL: Positive Outlook Due To Increased Healthcare SpendingJune 4, 2025 | seekingalpha.comAbrdn life sciences investors sees $145,135 stock sale by Saba CapitalMay 24, 2025 | investing.comSaba Capital Management, L.P. Sells 11,419 Shares of Abrdn Life Sciences Investors (NYSE:HQL) StockMay 23, 2025 | insidertrades.comSaba Capital Management, L.P. Sells 23,729 Shares of Abrdn Life Sciences Investors (NYSE:HQL) StockMay 20, 2025 | insidertrades.comSaba Capital Management, L.P. Sells 1,366 Shares of Abrdn Life Sciences Investors (NYSE:HQL) StockMay 9, 2025 | insidertrades.comThese 3 Funds Offer Sky-High Yields of 15% or More and Trade at a DiscountApril 30, 2025 | fool.comInsider Selling: Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Sells 9,144 Shares of StockApril 22, 2025 | insidertrades.comInsider Selling: Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Sells 15,400 Shares of StockApril 16, 2025 | insidertrades.comAbrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Sells 30,156 SharesApril 15, 2025 | insidertrades.comInsider Selling: Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Sells 6,889 Shares of StockApril 8, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHQL, BCAT, CET, and GSBD Company DescriptionsBlackRock Capital Allocation Term Trust NYSE:BCAT$15.02 +0.09 (+0.57%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$15.06 +0.04 (+0.23%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.-Central Securities NYSE:CET$49.99 +0.02 (+0.04%) As of 08/29/2025 04:00 PM EasternCentral Securities Corp. is a publicly owned investment manager. The firm invests in the public equity markets of the United States. It also invests on bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks and corporations. Central Securities Corp. was founded on October 1, 1929 and is based in New York City.Goldman Sachs BDC NYSE:GSBD$11.44 +0.03 (+0.22%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$11.45 +0.00 (+0.01%) As of 08/29/2025 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Goldman Sachs BDC, Inc. is a business development company specializing in middle market and mezzanine investment in private companies. It seeks to make capital appreciation through direct originations of secured debt, senior secured debt, junior secured debt, including first lien, first lien/last-out unitranche and second lien debt, unsecured debt, including mezzanine debt and, to a lesser extent, investments in equities. The fund primarily invests in United States. It seeks to invest between $10 million and $75 million in companies with EBITDA between $5 million and $75 million annually.abrdn Life Sciences Investors NYSE:HQL$13.92 +0.01 (+0.07%) Closing price 08/29/2025 03:58 PM EasternExtended Trading$13.92 0.00 (0.00%) As of 08/29/2025 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
